Lantheus Alpha Therapy, LLC - 06 Mar 2024 Form 4 Insider Report for Perspective Therapeutics, Inc. (CATX)

Reporting relationship: 10%+ Owner
Issuer ticker: CATX
Reported as of: 06 Mar 2024
Net transaction value: +$57,409,487
SEC form: 4
Accepted by SEC: 08 Mar 2024, 11:24:53 UTC
Prior SEC filing: 01 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Daniel Niedzwiecki Chief Administrative Officer and General Counsel, Lantheus

Key filing fact

Lantheus Alpha Therapy, LLC filed Form 4 for Perspective Therapeutics, Inc. (CATX) on 08 Mar 2024.

Key facts

This page summarizes Lantheus Alpha Therapy, LLC's Form 4 filing for Perspective Therapeutics, Inc. (CATX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Mar 2024, 11:24.

Change

Previous filing in this sequence was filed on 01 Feb 2024.
Current net transaction value: +$57,409,487.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CATX transaction

Common Stock

Purchase

Transaction value: $57,409,487
Shares: +60,431,039
Change %: +107%
Price: $0.9500
Shares after: 116,773,394
Date: 06 Mar 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Represents securities directly held by Lantheus Alpha Therapy, LLC, ("Lantheus"), a wholly owned direct subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held by Lantheus, which has direct beneficial ownership.